UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 193 ...

Cerus Corporation (NASDAQ:CERS) Q1 2021 Earnings Conference Call May 4, 2021 4:30 PM ET Company Participants Matt Notarianni - IR Obi Greenman - President and Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Carol Moore - Senior Vice President of Regulatory Affairs and Quality Jessica Hanover - Vice President of Corporate Affairs Conference Call Participants Josh Jennings - Cowen Mathew Blackman - Stifel Jacob Johnson - Stephens Operator Ladies and gen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 19 ...

Cerus Corporation (NASDAQ:CERS) Q4 2020 Results Earnings Conference Call February 25, 2021 4:30 PM ET Company Participants Matt Notarianni - Senior Director, Investor Relations Obi Greenman - President and CEO Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Carol Moore - Senior Vice President, Regulatory Affairs and Quality Conference Call Participants Nathan Leiphardt - Stephens, Inc. Matthew Blackman - Stifel Brandon Folkes - Cantor Fitzgerald Operator Ladies and gentlemen, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Preferred Share Purchase Rights (Title of Class) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Ye ...

Q3 2020 Earnings Call & Business Update October 29, 2020 cerus © Forward Looking Statements The following presentation contains forward-looking statements concerning Cerus' products, prospects and expected results, including statements relating to Cerus' 2020 annual product revenue guidance, including Cerus' reasons for narrowing its 2020 annual product revenue guidance; Cerus' belief in its longer term growth opportunities, including its expectation of continued increase in INTERCEPT adoption beyond the Ma ...

Cerus Corporation (NASDAQ:CERS) Q3 2020 Earnings Conference Call October 29, 2020 4:30 PM ET Company Participants Tim Lee - Investor Relations Obi Greenman - President and Chief Executive Officer Kevin Green - Chief Financial Officer Vivek Jayaraman - Chief Operating Officer Carol Moore - SVP of Regulatory Affairs and Quality Conference Call Participants Matthew Blackman - Stifel Mark Massaro - BTIG Jacob Johnson - Stephens Inc. Brandon Folkes - Cantor Fitzgerald Operator Ladies and gentlemen, thank you fo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act o ...

Financial Data and Key Metrics Changes - The company reported record product revenue of $21.5 million for Q2 2020, an 18% increase from $18.2 million in Q2 2019 [9][42] - Year-to-date product revenue reached $40.1 million, up 12% from $35.7 million in the first half of 2019 [42] - The net loss for Q2 2020 was $14.9 million, or $0.09 per diluted share, compared to a net loss of $17.6 million, or $0.13 per diluted share in the prior year [52] - The company ended Q2 2020 with approximately $136.5 million in cash, cash equivalents, and short-term investments [53] Business Line Data and Key Metrics Changes - Platelet kit sales in the U.S. showed robust year-over-year growth, accounting for approximately 82% of total kit sales, while plasma sales accounted for about 18% [12][45] - Government contract revenue from BARDA collaboration totaled $5.3 million in Q2 2020, compared to $4.3 million in the prior year [46] Market Data and Key Metrics Changes - The overall market opportunity for INTERCEPT platelets in the U.S. is approximately $150 million per year [17] - The American Red Cross has approximately 25% of their platelets now being INTERCEPT treated, with 20 of 23 production sites producing INTERCEPT platelets [13][16] Company Strategy and Development Direction - The company aims to capture as much of the U.S. INTERCEPT platelet market opportunity as possible over the next few years, with a goal for INTERCEPT to become the Standard of Care for platelets [17] - A five-year contract with the Hong Kong Red Cross was announced, representing a strategic account for expanding presence in the Asia-Pacific region [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving product revenue guidance of $89 million to $93 million for the year despite ongoing COVID-19 challenges [22] - The company is focused on ensuring support for blood center customers while preparing for two key product launches [60] Other Important Information - The company is on track for a PMA submission for pathogen-reduced cryoprecipitated fibrinogen complex by the end of the year, with potential FDA approval expected in early 2021 [25][26] - The INTERCEPT red blood cell program is progressing, with CE Mark approval expected in 2022 [40] Q&A Session Summary Question: What was the INTERCEPT platelet mix at the Red Cross at the end of 2019? - Management indicated that the American Red Cross has been steadily increasing their INTERCEPT platelet mix, with significant progress noted [61] Question: Is the seven-day U.S. platelet label just a label change? - Management confirmed that it is primarily a label change, which could enhance operational efficiency and justify a premium price for INTERCEPT [63][64] Question: What is the opportunity in Asia Pacific following the Hong Kong contract? - Management highlighted the importance of the Hong Kong Red Cross as a key opinion leader in the Asia-Pacific region, providing a critical entry point for further expansion [68][70] Question: Has the pace of INTERCEPT adoption changed with the FDA guidance deadline approaching? - Management noted that while there have been challenges due to COVID-19, there is a methodical move towards compliance with the FDA guidance, indicating solid growth in the U.S. platelet business [72]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 19 ...